Abstract
Background: COPD is frequently associated with comorbidities, the most serious and prevalent include lung cancer. Sirtuin 1 (SIRT1) is known to deacetylate histones and non-histone proteins including transcription factors thereby regulating metabolism, stress resistance, cellular survival, cellular senescence/aging. The aim of our study was to evaluate SIRT-1 expression in patients with lung squamous cell carcinoma and adenocarcinoma and these co-morbid with COPD.
Methods: 93 patients with lung nonsmall cell lung carcinoma co-morbid with moderate severity COPD (n=29) or without COPD were enrolled in the study. Lung function testing was performed within one week before lung surgery. SIRT-1 expression in cancer tissue was compared to control tissue (obtained from 15 autopsy cases) and analyzed by immunohistochemistry.
Results: Obtained results showed that in patients co-morbid with COPD and lung cancer, the SIRT-1 expression was higher in squamous cell carcinoma compared to patients without COPD (88 ± 26 vs. 42 ± 18 cell/ mm2; p=0.01). At the same time the SIRT-1 expression did not differ in adenocarcinoma and COPD co-morbidity specimens compared to those without COPD.
Conclusion: Patients with lung squamous cell carcinoma co-morbid with COPD have increased SIRT-1 expression if compared to carcinoma patients without COPD.
- Copyright ©ERS 2015